Treatment of sarcoidosis with infliximab

Chest

Volumn 127, Issue 3, 2005, Pages 1064-1071

  Doty, John D ^a   Mazur, Joseph E ^b   Judson, Marc A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Corticosteroids; Infliximab; Sarcoidosis; Therapy

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; CORTICOSTEROID; GADOLINIUM; HYDROXYCHLOROQUINE; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE; URSODEOXYCHOLIC ACID; GLUCOCORTICOID; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; CLINICAL ARTICLE; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; HYPOTENSION; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALE; MANIA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; PRIORITY JOURNAL; RASH; REVIEW; SACCHAROMYCES; SARCOIDOSIS; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; THRUSH; TREATMENT FAILURE; TUBERCULOSIS; UVEITIS; ARTICLE; IMMUNOLOGY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PREDNISONE; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15844414943     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.3.1064     Document Type: Article

References (34)

1. Winterbauer RH, Kirtland SH, Corey DE. Treatment with corticosteroids. Clin Chest Med 1997; 18:843-851
2. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. Chest 1999; 111:623-631
3. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88:1006-1010
4. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864-1868
5. Bradley D, Baughman RP, Raymond L, et al. Ocular manifestations of sarcoidosis. Semin Respir Grit Care Med 2002; 23:543-548
6. Mana J, Marcoval J, Graells J, et al. Cutaneous involvement in sarcoidosis: relationship to systemic disease. Arch Dermatol 1997; 133:882-888
7. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 1997; 18:853-864
8. Lower EE, Baughman RP. The use of low-dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299:153-157
9. Sharma OP, Vucinic V. Sarcoidosis of the thyroid and kidneys and calcium metabolism. Semin Respir Crit Care Med 2002; 23:579-588
10. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124:2023-2026
11. Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620-4627
12. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665-1669
13. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232
14. Pritchard C, Nadarajah K. Tumour necrosis factor-α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318-320
15. Judson MA, Baughman RP, Tierstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarc Vasc Diffuse Lung Dis 1999; 16:75-86
16. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135:747-760
17. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-740
18. Zheng L, Tescheler H, Guzman J, et al. Alveolar macrophage TNF-α release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995; 152:1061-1066
19. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115:36-42
20. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70-74
21. Mallbris L, Ljungberg A, Hedblad M, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-α therapy. J Am Acad Dermatol 2003; 48:290-293
22. Meyerle JH, Shorr A. The use of inflmmab in cutaneous sarcoidosis. J Drugs Dermatol 2003; 2:413-414
23. Roberts SD, Wilkes DS, Burgett RA, et al. Refractory sareoidosis responding to inflmmab. Chest 2003; 124:2028-2031
24. Katz JM, Bruno MK, Winterkorn JMS, et al. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 60; 426-430
25. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59:1660-1661
26. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 2001; 135:27-31
27. Baughman RP, Bradley DA, Raymond LA, et al. Double-blind, randomized trial of a tumor necrosis factor receptor antagonist (etanercept) for treatment of chronic ocular sarcoidosis [abstract]. Am J Respir Crit Care Med 2002; 165: A495
28. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-185
29. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21:241-248
30. Wagner C, Olson A, Ford J, et al. Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohn's disease [abstract]. Gastroenterology 2002; 122(suppl):A613-A614
31. Baert F, Noman M, Vermeire S, et al. Influence of immunogenioity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608
32. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-1104
33. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Grit Care Med 2003; 167:1279-1282
34. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158